Cargando…

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with significant mortality and morbidity. Approval of antifibrotic therapy has ameliorated disease progression, but therapy response is heterogeneous and to date, adequate biomarkers predicting therapy response are lacking. In recent years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seeliger, Benjamin, Carleo, Alfonso, Wendel-Garcia, Pedro David, Fuge, Jan, Montes-Warboys, Ana, Schuchardt, Sven, Molina-Molina, Maria, Prasse, Antje
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428132/ https://www.ncbi.nlm.nih.gov/pubmed/36059968 http://dx.doi.org/10.3389/fphar.2022.837680

Ejemplares similares

ANTIFIBROTIC THERAPY IN IDIOPATHIC PULMONARY FIBROSIS
por: Scullion, T., et al.
Publicado: (2017)

Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Li, Xiaohe, et al.
Publicado: (2019)

Antifibrotic Mechanism of Piceatannol in Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Sheng, Hanjing, et al.
Publicado: (2022)

Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis—Part B
por: Caliskan, Canay, et al.
Publicado: (2020)

Proteome Characterization of BALF Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Unveiling Undercover Molecular Pathways
por: Shaba, Enxhi, et al.
Publicado: (2021)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
por: Sugino, Keishi, et al.
Publicado: (2021)

The Antifibrotic and the Anticarcinogenic Activity of Capsaicin in Hot Chili Pepper in Relation to Oral Submucous Fibrosis
por: Huang, Zoufang, et al.
Publicado: (2022)

Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis
por: Kang, Jieun, et al.
Publicado: (2021)

The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
por: Limper, Andrew H.
Publicado: (2019)

Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?
por: Hadda, Vijay, et al.
Publicado: (2020)

Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications
por: Kelly, Bryan T., et al.
Publicado: (2021)

Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
por: Cottin, Vincent, et al.
Publicado: (2021)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
por: Collins, Bridget F., et al.
Publicado: (2019)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

The NLRP3-Inflammasome-Caspase-1 Pathway Is Upregulated in Idiopathic Pulmonary Fibrosis and Acute Exacerbations and Is Inducible by Apoptotic A549 Cells
por: Jäger, Benedikt, et al.
Publicado: (2021)

Effect of genotype on the disease course in idiopathic pulmonary fibrosis despite antifibrotic treatment
por: Sterclova, Martina, et al.
Publicado: (2021)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

Antifibrotic Effects of a Barbituric Acid Derivative on Liver Fibrosis by Blocking the NF-κB Signaling Pathway in Hepatic Stellate Cells
por: Wang, Yuan-Hsi, et al.
Publicado: (2020)

Antifibrotic Effect of a Novel Selective 11β-HSD2 Inhibitor (WZ51) in a rat Model of Myocardial Fibrosis
por: Zhuang, Fei, et al.
Publicado: (2021)

Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2018)

Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go
por: Assayag, Deborah
Publicado: (2021)

Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment
por: Kølner-Augustson, Line, et al.
Publicado: (2020)

Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment
por: Iwanami, Yuji, et al.
Publicado: (2022)

Antifibrotic therapy in idiopathic pulmonary fibrosis candidates for lung transplantation undergoing pulmonary rehabilitation
por: Pereira, Monica Pruss, et al.
Publicado: (2023)

A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia
por: Khan, Mohammed Ayaz, et al.
Publicado: (2023)

Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis
por: Mooney, Joshua, et al.
Publicado: (2021)

Reduced Sialylation and Bioactivity of the Antifibrotic Protein Serum Amyloid P in the Sera of Patients with Idiopathic Pulmonary Fibrosis
por: Chen, Wensheng, et al.
Publicado: (2020)

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
por: Mei, Qianru, et al.
Publicado: (2022)

Antifibrotic therapies to control cardiac fibrosis
por: Fan, Zhaobo, et al.
Publicado: (2016)

Quantification of dual-energy CT-derived functional parameters as potential imaging markers for progression of idiopathic pulmonary fibrosis
por: Scharm, Sarah C., et al.
Publicado: (2021)

Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis
por: Machahua, Carlos, et al.
Publicado: (2016)

Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives
por: Graney, Bridget A, et al.
Publicado: (2018)

Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust
por: Casillo, Valeria, et al.
Publicado: (2019)

Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry
por: Salisbury, Margaret L., et al.
Publicado: (2020)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment
por: Balestro, Elisabetta, et al.
Publicado: (2019)

Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
por: Wright, William Alexander, et al.
Publicado: (2021)

Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study
por: Yang, Cheng-Chun, et al.
Publicado: (2022)

Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
por: Suzuki, Yuzo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vccos48o87f406aue8ge8qsl58